Researchers investigated the capacity of NCT-58, a rationally-synthesized C-terminal HSP90 inhibitor, to kill trastuzumab-resistant HER2-positive breast cancer stem-like cells.
[Cell Death Discovery]
Sorry, but the selected Zotpress account can't be found.
